Your search for supplemental oxygen returned 110 results

Authors call for larger clinical trials to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for COVID-19

Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity

Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.

No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.

The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.

Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.